低分子右旋糖酐联用速尿对肾病综合征疗效观察被引量：3

Effect of dextran combination with flurosemide on nephrotic syndrome

导出

摘要目的 :观察低分子右旋糖酐联用速尿与白蛋白联用速尿治疗原发性肾病综合症疗效比较。方法 :18例原发性肾病综合症的病人 ,分别采用①速尿 (1mg·kg-1) +安慰剂 ;②速尿 (1mg·kg-1) +2 0 %白蛋白 5 0ml;③速尿 (1mg·kg-1) +2 5 0ml低分子右旋糖酐进行治疗 ,并测其 2 4h尿量 ,尿肌酐、尿钠、血心钠素 (ANP)、血尿素氮、血肌酐及血压。结果 :单用速尿能增加尿量及尿钠 (P <0 .0 5 ) ,但不增加血ANP。低分子右旋糖酐联用速尿或白蛋白联用速尿均能使尿量及尿钠、血ANP明显增加 (P <0 .0 5 ) ,低分子右旋糖酐联用速尿不引起肾功能的损害。结论 :低分子右旋糖酐能替代白蛋白起同等利钠利尿效果。 Objective To compare the diuretic effect of coadministration of dextran and flurosemide with that of coadministration of Albumin and flurosemide on primary nephrotic syndrome. Methods In a doutble-blind placebo-controlled study, eighteen primary nephrotic syndrome patients on standard sodium chloride intake, random by devided into three groups and received by intravenous administration for 60 minutes for three days (a) FU (1 mg·kg -1 ) combination with a sham infusion, (b) FU (1 mg·kg -1 ) combination with 50 ml of 20% solution of Albumin, or (c) FU (1mg/kg) combination with 250 ml dextran 40. Urinary volume, sodium and plasma atrial nartiuretic peptide concentration were assessed. Results The results showed that administration of FU alone increased mean cumulative urinary sodium and volume excretion as compared with the administration of sham infusion without treatment (P<0.05). The administration of FU and albumin or FU and dextran 40 caused an even more marked increase of urinary sodium and volume excretion (P<0.01), as compared with the administration of sham infusion without treatment. Plasma ANP increased significantly on both albumin infusion days and dextran 40 infusion days (P<0.05). Conclusion Coadministration of albumin and FU or dextran 40 and FU can increase the urinary volume and urinary Na and ANP significantly. dextran 40 can take the place of albumin because there was no difference between the administration of FU and albumin and FU and dextran in UV, Una and ANP.

作者陈星刘虹马志宏朱笑萍

机构地区中南大学湘雅二医院肾内科

出处《湖南医科大学学报》 CSCD 北大核心 2001年第4期374-376,共3页 Bulletin of Hunan Medical University

关键词右旋糖酐类速尿肾病综合症药物联合治疗 dextrans albumins flurosemide therapeutic use nephrotic syndrome

分类号 R692 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献6

1[1]Humphreys MH. Mechanisms and management of nephrotic edema[J]. Kidney Int, 1994,45:266-281.
2[2]Tulassay T, Rascher W, Lang RE, at al. Atrial natriuretic peptide and other vasoactive hormones in nephrotic syndrome[J]. Kidney Int, 1998,31:1391-1395.
3[3]Akcicedk F, Yalniz T, Basci A, et al. Diuretic effects of furosemide in patients with nephrotic syndrome: Is it potentiated by intravenous albumin?[J]. BMJ, 1995,310:162-163.
4[4]Weening JJ, Guldener VC, DAHA MR, et al. The pathophysiology of protein-overload proteinuria[J]. Am J Pathol, 1987,129:64-73.
5[5]Yoshimura A, Ideura T, Iwasaki S, et al. Aggravation of minimal change nephrotic syndrome by administration of human albumin[J]. Clin nephrol, 1992,37:109-114.
6[6]Sjostrom PA, Odlind BG, Beerman BA, et al. Pharmacokinetics and effects of furosemide in patients with the nephrotic syndrome[J]. Eur J Clin Pharmacol, 1998,37:173-180.